BRIEF published on 04/29/2026 at 13:44, 6 days 20 hours ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 6 days 20 hours ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
PRESS RELEASE published on 04/29/2026 at 13:39, 6 days 20 hours ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
BRIEF published on 04/20/2026 at 11:18, 15 days 22 hours ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
BRIEF published on 04/02/2026 at 19:05, 1 month 3 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
BRIEF published on 02/20/2026 at 21:42, 2 months 13 days ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 2 months 13 days ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 2 months 14 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
BRIEF published on 12/09/2025 at 14:55, 4 months 27 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 4 months 27 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
Published on 05/06/2026 at 09:01, 48 minutes ago Apex Widens and Extends Newly Discovered Zone with Significant NdPr Enrichment (>30%)
Published on 05/06/2026 at 02:17, 7 hours 32 minutes ago Troubadour Announces Share Consolidation and Effective Date
Published on 05/06/2026 at 02:00, 7 hours 49 minutes ago Vanta Announces Closing of First Tranche of Private Placement and Debt Settlement
Published on 05/06/2026 at 02:00, 7 hours 49 minutes ago Alset AI Announces Shares for Debt Transaction
Published on 05/06/2026 at 01:30, 8 hours 19 minutes ago Presentation to RIU Sydney Resources Roundup
Published on 05/06/2026 at 09:35, 13 minutes ago Huawei SPN Helps Yunnan Power Grid Build a Next-Gen High-Speed Bearer Network
Published on 05/06/2026 at 09:05, 43 minutes ago Jackery Launches Family Day Promotion with Exclusive Deals on Portable Power Solutions
Published on 05/06/2026 at 09:00, 48 minutes ago Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 05/06/2026 at 08:42, 1 hour 7 minutes ago Disclosure of shares outstanding and voting rights - 06.05.2026
Published on 05/05/2026 at 19:00, 14 hours 49 minutes ago Combined General Meeting of Air Liquide Shareholders of May 5, 2026
Published on 05/05/2026 at 18:03, 15 hours 45 minutes ago Aéroports de Paris SA - Shares and voting rights as of 30 April 2026
